Evidence map›Paper›PMID 37424400›Full record

ArticleEMBO reports2023

The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.

Bettina Röder, Hannah Fahnenstiel, Simon Schäfer, Bettina Budeus, Maria Dampmann, Melanie Eichhorn, Sieglinde Angermüller, Claudia Brost, Thomas H Winkler, Marc Seifert and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Bettina Röder *Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Hannah Fahnenstiel *Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Simon SchäferDivision of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Bettina BudeusMedical Faculty, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-9313-8636
Maria DampmannMedical Faculty, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-1418-3269
Melanie EichhornDivision of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Sieglinde AngermüllerDivision of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Claudia BrostDivision of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Thomas H WinklerDivision of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Marc SeifertMedical Faculty, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
Lars NitschkeDivision of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.ORCID 0000-0001-7236-379X
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Duisburg-Essen · DEEssen University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults in the Western world. B cell receptor (BCR) signaling is known to be crucial for the pathogenesis and maintenance of CLL cells which develop from mature CD5

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAnimalsB-LymphocytesHumansMiceMice, TransgenicProto-Oncogene ProteinsReceptors, Antigen, B-CellSialic Acid Binding Immunoglobulin-like LectinsProto-Oncogene ProteinsReceptors, Antigen, B-CellSialic Acid Binding Immunoglobulin-like LectinsBCR signalingCLLSiglec-10Siglec-G overexpressing miceSiglecs

Identifiers

PMID37424400
PMCPMC10398647
OpenAlexW4383710872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.